Tucotuzumab celmoleukin
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | EpCAM |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
339986-90-2  |
| ChemSpider | none |
| KEGG |
D09027 |
| Chemical and physical data | |
| Formula | C7812H12124N2044O2408S60 |
| Molar mass | 175.1 kg/mol |
| (verify) | |
Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[1][2][3]
This drug was developed by EMD Pharmaceuticals.
References
- ↑ Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin, American Medical Association.
- ↑ ClinicalTrials.gov
- ↑ National Cancer Institute: Definition of tucotuzumab celmoleukin
This article is issued from Wikipedia - version of the 6/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.